Valuation: Paion AG

Market Cap 1L 2L 1L 1L 2L 1.53Cr 2L 15.81L 6L 80.36L 6L 6L 2.53Cr P/E 2021
-3.89x
P/E 2022 -53x
Enterprise Value 98.67L 1.1Cr 90.76L 82.24L 1.54Cr 104.61Cr 1.57Cr 11Cr 4.34Cr 55Cr 4.13Cr 4.05Cr 173.54Cr EV / Sales 2021
14.1x
EV / Sales 2022 1.22x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
3 months-16.36%
6 months+3.37%
Current year+248.48%
1 week 0.05
Extreme 0.046
0.05
1 month 0.05
Extreme 0.046
0.06
Current year 0.01
Extreme 0.012
0.23
1 year 0.01
Extreme 0.012
0.23
3 years 0
Extreme 0.0001
0.36
5 years 0
Extreme 0.0001
18.34
10 years 0
Extreme 0.0001
36.78
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2023
Director of Finance/CFO - 01/06/2022
Director TitleAgeSince
Director/Board Member 65 01/10/2012
Director/Board Member 75 01/06/2017
Director/Board Member - 22/05/2019
Date Insider Type Main position Quantity % Market Cap. Importance
27/12/22 Buy

Director

1,121 0.0016%
12/01/21 Buy

Chief Executive Officer

8,500 0.0127%
08/06/20 Buy

Chief Executive Officer

13,158 0.0202%
Change 5-day change 1-year change 3-year change Capi.($)
+32.61%0.00%+198.70%-86.49% 4L
-0.62%+0.50%+33.92%+60.07% 6.44TCr
+0.35%+3.20%+14.92%+84.55% 5.62TCr
+0.53%+1.96%+15.37%+106.81% 5.42TCr
-3.63%-5.07%+22.51%+49.70% 4.53TCr
+0.08%-1.40%+20.81%+99.53% 4.22TCr
-0.78%+1.15%+221.28%+930.74% 4.08TCr
+3.27%+47.96%+112.67%+96.48% 3.38TCr
+1.22%-1.39%+13.92%+46.95% 3.22TCr
-1.29%-1.72%+21.00%-6.85% 2.36TCr
Average -0.11%+4.25%+67.51%+138.15% 3.93TCr
Weighted average by Cap. -0.19%+3.64%+49.74%+161.53%

Financials

2021 2022
Net sales 71.28L 79.59L 65.57L 59.41L 1.11Cr 76Cr 1.13Cr 7.82Cr 3.14Cr 40Cr 2.99Cr 2.92Cr 125.37Cr 3.32Cr 3.71Cr 3.06Cr 2.77Cr 5.18Cr 352.49Cr 5.28Cr 36Cr 15Cr 185.42Cr 14Cr 14Cr 584.75Cr
Net income -2.18Cr -2.43Cr -2Cr -1.82Cr -3.39Cr -230.97Cr -3.46Cr -24Cr -9.59Cr -121.5Cr -9.13Cr -8.93Cr -383.15Cr -6L -6L -5L -5L -9L -6.14Cr -9L -63.51L -25.5L -3.23Cr -24.26L -23.75L -10Cr
Net Debt 1.38Cr 1.54Cr 1.27Cr 1.15Cr 2.15Cr 145.98Cr 2.19Cr 15Cr 6.06Cr 77Cr 5.77Cr 5.65Cr 242.16Cr 97.23L 1.09Cr 89.44L 81.04L 1.51Cr 103.08Cr 1.54Cr 11Cr 4.28Cr 54Cr 4.07Cr 3.99Cr 171Cr
Logo Paion AG
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Employees
64
Date Price Change Volume
29/26/29 €0.0460 0.00% 0
28/26/28 €0.0460 0.00% 0
27/26/27 €0.0460 0.00% 0
26/26/26 €0.0460 0.00% 0
23/26/23 €0.0460 0.00% 0
  1. Stock Market
  2. Stocks
  3. PA8K Stock